Latest news
Stay in the know about our progress, and visit our Newsroom
Galapagos,
your partner of choice
Combining scientific excellence, financial capacity and BD experience, we believe in the power of strong partnerships to pioneer for patients, together
To achieve our ambitious goals, we evaluate and access external innovation. We are scouting for the best science, products, and people to complement our internal assets and capabilities, with the aim of building a balanced portfolio of best-in-class medicines across modalities and development stages in our core therapeutic areas.
We will continue to evaluate multiple product candidates and business development opportunities to leverage our internal capabilities further, and accelerate and expand our pipeline of potential best-in-class investigational medicines in our therapeutic focus areas of immunology and oncology.
Our value proposition
Galapagos, a trusted partner
Scientific excellence
– Deep expertise in small molecules, CAR-T and biologics
– Broad industry network
Financial capacity
– Strong balance sheet
– Strategic Gilead partnership
Unique expertise
– Highly experienced BD team
– Strong European ecosystem presence
– Agile decision making
Partnerships to build our CEll therapy capabilities
Landmark Bio is collective endeavor bringing together leaders in industry, academia, and research hospitals to accelerate development and industrialization of next-generation genomic medicines. Landmark Bio will perform GMP manufacturing of clinical trial batches of Galapagos’ development programs of chimeric antigen receptor (CAR) T-cell therapies in hematology-oncology in the Boston metropolitan area.
Thermo Fisher Scientific Inc. is the world leader in serving science. They provide GMP manufacturing as well as BioServices and Specialty Logistics for Galapagos’ CAR-T hemato-oncology clinical program in the San Francisco area.
Blood Centers of America (BCA) is the largest blood supply network in the United States. BCA’s national network of blood centers will provide decentralized manufacturing services for Galapagos’ CAR-T product candidates, close to cancer treatment centers. The collaboration enables rapid deployment of Galapagos’ decentralized CAR-T platform across the U.S., improving patient access to potentially life-saving CAR-T treatments.
Excellos Inc., a cell therapy contract development and manufacturing organization (CDMO) and member of Blood Centers of America (BCA), has been selected as decentralized manufacturing unit to support Galapagos’ CAR-T cell therapy clinical study in the San Diego area. Excellos will manufacture Galapagos’ CAR-T cell therapy candidate, GLPG5101, for the FDA-cleared ATALANTA-1 clinical study, which targets patients with relapsed/refractory non-Hodgkin lymphoma in the U.S.
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Galapagos and Catalent announced a collaboration to further expand Galapagos’ Decentralized CAR-T Manufacturing Network in the U.S. Catalent’s commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing for Galapagos’ upcoming trials in New Jersey, New York, and surrounding areas.
NecstGen is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to Cell and Gene Therapies. They have a strategic collaboration with Galapagos to support decentralized manufacturing of Galapagos’ candidate cell therapy products in Europe. The partnership underscores both NecstGen’s and Galapagos’ commitment to advancing innovative therapies and bridging the gap between the translation of research, to large clinical trials, and bring products to patients.
Lonza is a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets. Galapagos uses Lonza’s Cocoon® for its decentralized, innovative T-cell manufacturing platform near the patient. The platform consists of an end-to-end xCellit® workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control testing and release strategy.
Collaborations, equity investments And M&A to expand our pipeline
CellPoint was a biotechnology company founded in 2018 in the Netherlands. They developed a decentralized CAR-T manufacturing model. CellPoint was acquired by Galapagos in 2022 to accelerate access to next-generation cell therapies.
Abound Bio was a US company whose mission was to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease. Abound Bio was acquired by Galapagos in 2022 to accelerate access to next-generation cell therapies.
Acquiring CellPoint and Abound Bio brought a broader portfolioand breakthrough capabilities to Galapagos
BridGene is a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates. Galapagos established strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology.
Frontier Medicines is a pioneer in precision oncology with a unique technology platform and a pipeline of potential best-in-class assets that fit with Galapagos’ precision oncology R&D approach. Galapagos participated in Series C financing round of Frontier Medicines. The investment aligns with Galapagos’ innovation acceleration strategy to bring transformational medicines to patients around the world.
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company’s unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Galapagos signed a clinical collaboration agreement with Adaptimmune with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications.
Pioneering for patients, together
Collaborate with us!
If you believe your assets fit Galapagos’ strategy or like to learn more about our in-licensing or partnering efforts, please contact our Business Development team.
Please note that any business development proposals that are submitted to Galapagos via email or via our website will be considered non-confidential. No information exchange may be deemed confidential without a signed confidentiality or disclosure agreement from Galapagos.
Our stories
Read more about how we are #LivingInnovation in our stories
Investor hub
Looking for information about our company, our stock and our financials?